The estimated Net Worth of Biotech Capital Ii Gp Llcba... is at least $250 Million dollars as of 22 September 2003. Biotech Llcba owns over 71,100 units of Seagen Inc stock worth over $249,779,406 and over the last 21 years Biotech sold SGEN stock worth over $0.
Biotech has made over 2 trades of the Seagen Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Biotech bought 71,100 units of SGEN stock worth $353,367 on 22 September 2003.
The largest trade Biotech's ever made was buying 556,350 units of Seagen Inc stock on 19 September 2003 worth over $2,804,004. On average, Biotech trades about 57,041 units every 0 days since 2003. As of 22 September 2003 Biotech still owns at least 1,091,407 units of Seagen Inc stock.
You can see the complete history of Biotech Llcba stock trades at the bottom of the page.
Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro..., and Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: